Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC8091 | Pyridostatin trifluoroacetate salt Featured |
Pyridostatin stabilizes G-quadruplexes, targeting the proto-oncogene SRC and telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest.
More description
|
![]() |
DC7257 | PYR 41 Featured |
PYR-41 is a specific and cell permeable inhibitor of ubiquitin-activating enzyme E1 with an IC50 of < 10 uM, with no or little activity at E2.
More description
|
![]() |
DC7992 | PX 12 Featured |
PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1(Trx-1) currently in clinical development as an antitumor agent; IC50=7 uM in Hela, MTT assay, 72 h.
More description
|
![]() |
DC7256 | Purvalanol B(NG-95) Featured |
Purvalanol B(NG-95) is a cyclin-dependent kinase inhibitor with IC50 values of 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively.
More description
|
![]() |
DC7255 | Purmorphamine Featured |
Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM and also is an inducer of osteoblast differentiation with EC50 of 1 μM.
More description
|
![]() |
DC8495 | PTC-209 hydrobromide Featured |
PTC-209 is a specific inhibitor for BMI-1 with IC50 of 0.5 uM in in both GEMS reporter and ELISA assays.
More description
|
![]() |
DC7485 | PTC-209 Featured |
PTC-209 is a specific inhibitor for BMI-1 with IC50 of 0.5 uM in in both GEMS reporter and ELISA assays.
More description
|
![]() |
DC2005 | PTC124 (Ataluren) Featured |
PTC124 (Ataluren) is a potent nonsense mutation inhibitor with EC50 of ~0.1 μM.
More description
|
![]() |
DC10464 | PT2385 Featured |
PT2385 is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity.
More description
|
![]() |
DC6308 | Sofosbuvir(PSI7977,GS-7977) Featured |
PSI-7977 is an investigational nucleotide analog currently in Phase 2 for treatment of chronic HCV infection.
More description
|
![]() |
DC4121 | PSI6130 Featured |
PSI-6130(R 1656) is a Hepatitis C Virus Nucleoside Inhibitor. PSI-6130(R 1656) is useful for Antiviral agents.
More description
|
![]() |
DC9269 | PRT4165(NSC-600157) Featured |
PRT4165 is a potent inhibitor of PRC1 (Polycomb-repressive complex 1)-mediated H2A ubiquitylation.
More description
|
![]() |
DC10397 | Proguanil Featured |
Proguanil is an antimalarial prodrug that is metabolized to the active metabolite cycloguanil, a dihydrofolate reductase (DHFR) inhibitor.
More description
|
|
DC10070 | PRIMA-1MET(APR-246) Featured |
PRIMA-1MET is methylated derivative of PRIMA-1. It can restore mutant p53 activity.
More description
|
![]() |
DC9805 | Preladenant(SCH420814) Featured |
Preladenant(SCH 420814) is a potent and selective antagonist at the adenosine A2A receptor.
More description
|
![]() |
DC8347 | PRE-084 hydrochloride Featured |
PRE-084 hydrochloride is a high affinity, selective σ1 agonist (Ki values are 2.2 and 13091 nM for σ1 and σ2 receptors respectively).
More description
|
![]() |
DC11526 | Praliciguat Featured |
Praliciguat (IW-1973, IW1973) is a potent, orally available sGC stimulator that concentration-dependently increases the production of cGMP with EC50 of 267 nM.
More description
|
![]() |
DC7280 | Pracinostat(SB939) Featured |
Pracinostat(SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6; has no activity against the class III isoenzyme SIRT I.
More description
|
![]() |
DC7252 | PR-619 Featured |
PR-619 is a broad-range DUB inhibitor with potential for further development as a chemotherapeutic agent in cancer therapy.
More description
|
![]() |
DC7483 | PPQ-102 Featured |
PPQ-102 is a potent CFTR inhibitor which can completely inhibited CFTR chloride current with IC 50approximately 90 nM.
More description
|
![]() |
DC7482 | Torkinib (PP242) Featured |
PP242 is a selective mTOR inhibitor with IC50 of 8 nM; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively; also showed slightly weaker activity against BRD4 (Kd= 1.7 uM).
More description
|
![]() |
DC5008 | PP2(AGL 1879) Featured |
PP2 is Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
More description
|
![]() |
DC9931 | PP2 analog Featured |
PP2 analog is the analog of PP2,a Src family kinase inhibitor.
More description
|
![]() |
DC5007 | pp1 Featured |
PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
More description
|
![]() |
DC7704 | Poziotinib Featured |
Poziotinib, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.
More description
|
![]() |
DC7251 | AM 281 Featured |
Potent, selective CB1 cannabinoid receptor antagonist/inverse agonist (Ki values are 12 and 4200 nM for CB1 and CB2 receptors respectively). Increases locomotor activity following systemic administration in vivo. Analog of SR141716A (Ki = 14 nM).
More description
|
![]() |
DC7574 | FIPI Featured |
Potent phosholipase D (PLD) inhibitor (IC50 values are 20 and 25 nM for PLD2 and PLD1 respectively).
More description
|
![]() |
DC8022 | R-268712 Featured |
Potent and selective inhibitor of the TGF-β type I receptor/ALK5 (IC50 = 2.5 nM). Exhibits ~ 5000-fold selectivity over p38 MAPK. Suppresses development of renal fibrosis in a unilateral ureteral obstruction model. Also reduces proteinuria, glomeruloscler
More description
|
![]() |
DC9742 | Ponesimod Featured |
Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.
More description
|
![]() |
DC7588 | PNU120596 Featured |
PNU-120596 is a positive allosteric modulator of α7 nAChR with EC50 of 216 nM.
More description
|
![]() |